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Abstract
Introduction A significant survival improvement after
postmastectomy radiotherapy was identified in the Danish
Breast Cancer Cooperative Group (DBCG82) b and c studies
and in the British Columbia Randomized Radiation Trial.
Recently, potential predictive value regarding response to
postmastectomy radiotherapy was reported for carbonic
anhydrase (CA) IX in a study (reported in abstract form) that
included 160 patients. The purpose of the present study was to
examine the importance of CA IX to response to
postmastectomy radiotherapy in the larger scaled DBCG82 b
and c studies.
Methods The DBCG82 b and c studies included 3,083 high-
risk Danish breast cancer patients. The women were randomly
assigned to postmastectomy radiotherapy plus systemic
therapy (cyclophosfamide, methotrexate and fluorouracil in
premenopausal women; and tamoxifen in postmenopausal
women) or to systemic therapy alone. Cores from invasive
tumour-containing paraffin blocks from 1,000 patients (more
than seven nodes surgically removed) were transferred to tissue
microarrays. Tissue microarray sections were stained
immunohistochemically for CA IX (M75). The median follow up
for patients remaining alive was 17 years. Clinical end-points
were loco-regional recurrence, distant metastases, disease-
specific survival and overall survival. Statistical analyses
included κ statistics, χ2 or exact tests, Kaplan-Meier probability
plots, Log-rank test and Cox regression analyses.
Results CA IX was assessable in 945 cores. The percentage of
tumours positive for CA IX was 16% (≥ 10% invasive tumour
staining). CA IX was not an independent prognostic marker for
survival, distant metastases, or locoregional recurrence in the
subgroup of 945 patients or within either of the two
randomization arms. In subgroup analyses, however, CA IX was
an independent prognostic marker for overall survival among
postmenopausal women (P = 0.001), women with one to three
positive nodes (P = 0.02) and hormone receptor positive
women (P = 0.001). Fifteen-year probabilities of overall survival
were improved by 9% and 7% after postmastectomy
radiotherapy for the subgroups of CA IX negative and CA IX
positive patients, respectively.
Conclusion Within this series of 945 high-risk premenopausal
and postmenopausal women, positivity for CA IX was not overall
an independent prognostic marker for survival; only in subgroup
analyses was it found to have prognostic value. The
improvement in 15-year survival after postmastectomy
radiotherapy was of similar magnitude in the two subgroups of
CA IX positive and CA IX negative patients.Page 1 of 10
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CA = carbonic anhydrase; CMF = cyclophosfamide, methotrexate and fluorouracil; CI = confidence interval; DBCG82 = Danish Breast Cancer Coop-
erative Group; DM = distant metastases; DSS = disease-specific survival; ER = oestrogen receptor; HER = human epidermal growth factor; HR = 
hazard ratio; LRR = locoregional recurrence; OS = overall survival; PgR = progesterone receptor; PMRT = postmastectomy radiotherapy; TMA = 
tissue microarray.
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The zink metalloenzyme carbonic anhydrase (CA) IX is a trans-
membrane glycoprotein that reversibly converts carbon diox-
ide and water to carbonic acid. CA IX has been shown to play
an important role in pH regulation and its expression has been
suggested, in response to hypoxia, to reduce the pericellular
pH and facilitating breakdown of the extracellular matrix [1]. In
addition, it may play a role in cell proliferation and cellular
transformation [2] as well as in adaptation of tumour cells to
hypoxic conditions [3-5]. It is well known that the response of
cells to radiation is dependent on oxygen [6], and conse-
quently CA IX has been linked to response to radiotherapy [7-
9].
CA IX over-expression in breast cancer has been associated
with over-expression of human epidermal growth factor
(HER)2 [10] and with reduced survival [11,12]; Cox multivari-
ate regression analyses have revealed these associations to
be statistically significant [7,8,13,14]. In the largest study con-
ducted to date in this area (including 400 patients), the prog-
nostic effect of CA IX was restricted to premenopausal
women also treated with tamoxifen and to premenopausal
women not treated with tamoxifen and with one to three posi-
tive lymph nodes [8]. Additionally, the gene encoding CA IX
was among the 231 that were most upregulated or downreg-
ulated in the studies conducted by Van't Veer and coworkers
[15,16], in which the 70-gene signature was discovered.
Chia and coworkers [7] recently examined the predictive value
of CA IX in the 160 out of 318 patients who were randomly
assigned to postmastectomy radiotherapy (PMRT). By apply-
ing immunohistochemical analyses to tissue microarrays
(TMAs), the investigators found that 23% of tumours were
positive for CA IX (with at least one invasive tumour cell stain-
ing being deemed to represent positivity). Positivity for CA IX
was an independent prognostic marker for reduced survival.
Furthermore, significantly improved survival after PMRT was
found among CA IX positive patients but not in the larger
group of CA IX negative patients. These results are in disa-
greement with the theory that aggressive tumours (character-
ized by independent prognostic markers of reduced survival)
will, at an early time point in the pathogenesis, seed tumour
cells to distant sites where they can develop into distant
micrometastases. If these distant micrometastases addition-
ally were resistant to the systemic therapy applied, then PMRT
– which eliminates tumour cells in the radiated area only –
would not result in improved survival for this poor prognosis
group. Furthermore, the findings are in disagreement with the
theory that CA IX positive status is a hypoxic marker and is
associated with increased radio-resistance, and is therefore
associated with reduced improvement in locoregional recur-
rence (LRR) control and subsequently survival after PMRT.
We should like to test three hypotheses. First, we hypothesize
that positive CA IX status is an independent prognostic marker
for increased invasive potential, and thereby is associated with
increased probability of LRR, distant metastases (DM), and
reduced survival. Second, we hypothesize, counter to the find-
ings presented thus far, that if positive CA IX status is an inde-
pendent marker of reduced survival then an improvement in
survival after PMRT will be restricted to CA IX negative
patients. Finally, we hypothesize that CA IX positive patients
experience a smaller reduction in LRR after PMRT as com-
pared with CA IX negative patients.
Materials and methods
Patients
Twenty-seven patients with at least two paraffin blocks from
the same primary tumour were selected from a cohort
described previously [17]. They were included in a pilot study
comparing staining of TMA biopsies with staining of whole
sections.
In addition, a subgroup, extracted from among the 3,083 high-
risk Danish breast cancer patients included in the Danish
Breast Cancer Cooperative Group (DBCG82) b and c studies
in the period from 1982 to 1989, was selected for biological
analyses. The 3,083 DBCG82 patients have been described
previously [18,19]. In brief, high risk was defined as either pos-
itive lymph nodes and/or tumour size larger than 5 cm and/or
invasion of tumour to surrounding skin or pectoral fascia. All
women had undergone a total mastectomy and a partial axillary
dissection. The premenopausal women were enrolled in the
DBCG82 b protocol and were randomly assigned to receive
either radiotherapy plus CMF (cyclophosfamide, methotrexate
and fluorouracil) chemotherapy (eight cycles) or to CMF
chemotherapy alone (nine cycles) [18]. The postmenopausal
women were enrolled in the DBCG82 c protocol and were
randomly assigned to either radiotherapy plus tamoxifen (30
mg daily/1 year) or to tamoxifen alone [19]. Recently, long-
term clinical follow up in these patients was reported [20].
Median follow-up time was 17 years for patients remaining
alive. The subgroup, selected for biological analyses, included
1,078 patients; for all of these patients paraffin blocks were
available and more than seven lymph nodes were surgically
removed (median seven lymph nodes removed).
Methods
At least two paraffin-embedded tumour blocks from each of
the 27 patients included in the pilot study and at least one from
each of 1,078 DBCG82 b and c patients were collected, sec-
tioned, and stained with haematoxylin and eosin. Invasive
tumour was verified and marked on all 54 paraffin blocks from
the pilot study and on 1,000 out of the 1,078 DBCG82 paraf-
fin blocks. A central core and a peripheral 1 mm TMA core
punched from the area previously identified as including inva-
sive tumour were transferred to TMAs from each of the 54 par-
affin blocks. Only a central 1 mm core from each of the 1,000
DBCG82 paraffin blocks was transferred to TMAs. All TMAsPage 2 of 10
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stored at 4°C until manual staining for CA IX.
Handling of the biological material was previously described in
detail, including TMA construction and immunohistochemical
staining for oestrogen receptor (ER) and progesterone recep-
tor (PgR), and immunohistochemical staining and fluoresence
in situ hybridization analyses for the HER2 receptor [21].
Before immunohistochemical staining for CA IX, de-paraffini-
zation with 99% ethanol, blocking of the endogen peroxidase
with H2O2, and epitope retrieval by microwave was performed.
Sections were immunohistochemically stained for CA IX with
the monoclonal antibody M75 at a dilution of 1:2,500. The
ability of this antibody to detect CA IX expression specifically
in tissue sections was previously confirmed by direct correla-
tion with Western blot analysis in human breast tumour spec-
imens [22].
The sections were incubated overnight at a temperature of
4°C. On day 2 the sections were incubated with a peroxidase
conjugated to goat antimouse immunoglobulins (DAKO Envi-
sion Mouse, K4001; Dako, Glostrup, Denmark) for 60 minutes
at room temperature. Afterward, sections were stained with
DAB (K3468; Dako) and counterstained with haematoxylin.
Sections from a control TMA, including invasive breast tumour
cores previously determined to be CA IX positive and nega-
tive, were stained with and without primary antibody as well. All
sections from the pilot study were scored semiquantitatively
by two observers, and sections from the DBCG82 b and c
studies were scored semiquantitatively by one observer. If
there was any doubt regarding the scoring of the DBCG82 b
and c sections, then a second observer was consulted and
consensus was reached on the diagnosis. Percentage of
tumours with membrane staining for CA IX was recorded. In
the DBCG82 b and c studies membrane staining in at least
10% of invasive tumour was scored as positive.
Statistical analyses and end-points
The pilot study was analyzed using κ statistics. In the
DBCG82 b and c studies χ2 or exact tests were used to test
relationships between variables. Kaplan-Meier survival proba-
bility curves were constructed and evaluated for differences
using a log-rank test. The prognostic value of CA IX was ana-
lyzed using Cox univariate and multivariate regression analy-
ses. Tests of interactions were applied to Cox multivariate
regression analyses as well. P < 0.05 was regarded to indi-
cate statistical significance, and all estimated P values were
two tailed. Statistical end-points were isolated LRR, DM, dis-
ease-specific survival (DSS) and overall survival (OS). Hazard
ratios (HRs) provided on Kaplan-Meier OS probability plots
were HRs of overall mortality. Statistical calculations were per-
formed using the statistical program STATA version 8.2 (Stat
Corp., College Station, TX, USA).
Results
Pilot study examining agreement between different CA 
IX stainings
The κ values varied when cut-points determining CA IX tumour
positivity was changed (Table 1). Comparing a 1 mm TMA
core with the corresponding whole section, a high level of
agreement was found using a cut-point of at least 10% of inva-
sive tumour staining. In addition, a high level of agreement was
found using central biopsies as compared with peripherally
biopsies, both comparing TMA cores with whole sections and
comparing TMA cores from two different paraffin blocks from
the same tumour. In fact, κ values were of almost the same
magnitude using central cores and a cut-point of 10%, as
found when comparing stainings of two different whole sec-
tions from the same tumour (observer 1: κ = 0.71 versus κ =
0.72; and observer 2: κ = 0.65 versus κ = 0.74). However,
caution should be exercised when comparing κ values
because they are dependent on distribution, and a slightly
higher frequency of CA IX positive tumors was found in the
whole sections (28%) as compared with the TMA cores
(24%) at a cut-point of 10%. Nevertheless, tables showed the
same percentage of discordant cases when comparing CA IX
stainings of TMA sections with stainings of corresponding
whole sections, and when comparing two whole sections
(observer 1: 6/54 versus 3/27; observer 2: 6/54 versus 3/27;
tables not presented). Adding positive CA IX information from
one extra core to the CA IX information already obtained was
shown only to increase the percentage of CA IX positive
tumours slightly from 28% to 32% for observer 1 and from
23% to 27% for observer 2 (Figure 1). Adding information
from two or three extra cores did not further increase the fre-
quency of CA IX positive tumors. A high interobserver agree-
ment was found both scoring TMA cores and scoring whole
sections, with κ values exceeding 0.80 (data not presented).
DBCG82 b and c studies
The subgroup of 1,000 patients was well distributed between
the two randomization arms for all classical clinicopathological
parameters, including CA IX (Table 2).
Frequency of CA IX
Immunohistochemical staining for CA IX was performed suc-
cessfully for 945 out of the 1,000 patients, applying a thresh-
old of at least 10 invasive tumour cells needed to score the
slide. A total of 151 out of 945 patients (16%) were classified
as being CA IX positive using a cut-point of ≥ 10% invasive
tumour staining for CA IX. Applying cut-points of at least one
tumour cell, and ≥ 20% and ≥ 30% invasive tumor staining for
CA IX, the percentages of CA IX positive tumours were 26%,
13% and 10%, respectively.
Prognostic value of CA IX
Positive CA IX staining was significantly associated with other
markers of poor prognosis such as grade 3 malignant tumours,
hormone receptor negative tumours and HER2 positivePage 3 of 10
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tumour size (Table 3).
In univariate analyses of the 945 patients with assessable CA
IX stainings, positive CA IX status was significantly associated
with increased overall mortality (HR 1.30, 95% confidence
interval [CI] 1.06 to 1.60) and disease-specific mortality (HR
1.29, 95% CI 1.02 to 1.62), but not with increased probability
of DM (HR 1.23, 95% CI 0.98 to 1.54) or increased probabil-
ity of LRR (HR 1.28, 95% CI 0.82 to 2.01). However, the sig-
nificance of the associations of positive CA IX staining with
overall and disease-specific mortality disappeared in multivar-
iate analysis (P = 0.2), after correction for positive lymph
nodes, tumour size, grade of malignancy, hormone receptor
and HER2 receptor status, menopausal status/systemic
treatment, and randomization, which were all independent
prognostic markers. Excluding hormonal receptor status from
the multivariate analysis did not change this finding.
Multivariate subgroup analyses were performed for all sub-
groups of patients presented in Table 3. Positive CA IX was
significantly associated with increased overall mortality only in
the subgroups of postmenopausal women (P = 0.005),
women with one to three positive lymph nodes (P = 0.04),
women with ER-positive tumours (P = 0.003) and women with
PgR-positive tumours (P = 0.03). To compare our results with
those reported by Brennan and coworkers [8], we conducted
further subgroup analyses of the premenopausal women.
Those analyses showed that CA IX was not an independent
prognostic marker of overall mortality among premenopausal
women with one to three positive lymph nodes (P = 0.3), but
it was among premenopausal women with more than three
positive lymph nodes (P = 0.05). CA IX has been suggested
to be an intervening variable in ER downregulation, which was
why it was excluded from multivariate analyses by Brennan
and coworkers [8]. However, when hormone receptor status
was excluded from the multivariate analysis of premenopausal
women with more than three positive lymph nodes, the statis-
tical significance of the finding disappeared (P = 0.4). Interest-
ingly, in the subgroup of postmenopausal women (who were
additionally treated with tamoxifen), CA IX was a stronger
prognostic marker of overall mortality, as was hormone recep-
tor status. Performing further subgroup analyses of the post-
menopausal women showed that when this group was further
separated according to randomization status, CA IX was sig-
nificantly associated with overall mortality only within the sub-
group of women randomly assigned to radiotherapy (P = 0.03)
and it was a stronger prognostic marker of overall mortality, as
was hormonal receptor status (P = 0.3). Finally, a subgroup
analysis of hormone receptor positive women revealed that
CA IX was an independent prognostic marker of OS only in
the subgroup of postmenopausal women.
Table 1
Kappa values
One cell ≥ 10% invasive tumour staining ≥ 20% invasive tumour staining
Obs. 1 Obs. 2 Obs. 1 Obs. 2 Obs. 1 Obs. 2
TMA biopsy versus whole section (central) 0.56 0.51 0.71 0.65 0.68 0.61
TMA biopsy versus whole section (peripheral) 0.52 0.37 0.59 0.59 0.59 0.58
Two different paraffin blocks (central biopsies) 0.72 0.56 0.69 0.86 0.89 0.86
Two different paraffin blocks (peripheral biopsies) 0.66 0.33 0.42 0.49 0.41 -0.07
Whole sections (two different paraffin blocks) 0.70 0.55 0.72 0.74 0.70 0.70
Presented are κ values that describe comparisons between immunohistochemial stainings for carbonic anhydrase IX of 108 tissue microarray 
biopsies and 54 whole sections from 27 breast carcinomas. The κ values are presented for two observers and using different cut-points for 
determining positivity.
Figure 1
Immunohistochemical analyses of CA IX on TMAs. The tissue microar-
rays (TMAs) were scored by two observers: observer 1 (Obs. 1) and 
observer 2 (Obs. 2). Only tumours that were interpretable on all four 
cores were included in this analysis. The left-most bar in each group 
(TMA 1) gives the frequency of tumour positivity in one TMA core. The 
subsequent bars (moving from left to right) show the tumour positivity 
observed after adding information from addtional cores.Page 4 of 10
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one tumour cell, or ≥ 20% or ≥ 30% invasive tumour staining
did not improve the prognostic value of positive CA IX staining
in the total group of 945 patients.
CA IX and response to PMRT
Kaplan-Meier probability plots of OS after PMRT among CA IX
positive and CA IX negative patients revealed improved sur-
vival after PMRT in both subgroups of patients (Figure 2). Fif-
teen-year OS probabilities were improved by 7% and 9% after
PMRT for the subgroups of CA IX positive and CA IX negative
patients, respectively. The HR of overall mortality after PMRT
was 0.87 (95% CI 0.60 to 1.27) for the small subgroup of 151
CA IX positive patients and 0.82 (95% CI 0.69 to 0.97) for the
large subgroup of 813 CA IX negative patients. HRs and 95%
CIs after PMRT did not differ significantly between CA IX pos-
itive and CA IX negative patients for OS, DSS, DM, or LRR
(Table 4). In multivariate analysis by Cox regression, no signif-
icant interaction was found between CA IX and randomization
status for any of the four end-points. Similar tendencies were
observed when the women were separated into premenopau-
sal and postmenopausal women, and into women with one to
three positive nodes and those with more than three positive
nodes.
Table 2
Distribution of clinicopathological parameters in 1,000 high-risk breast cancer patients
Radiotherapy No radiotherapy χ2
All 489 (49%) 511 (51%)
Protocol Pre (DBCG82b) 267 (54%) 296 (58%) 0.3
Post (DBCG82c) 222 (46%) 215 (42%)
Tumour size (mm) <21 171 (35%) 190 (37%) 0.1
21 to 50 259 (53%) 242 (47%)
>50 59 (12%) 79 (15%)
Positive nodes None 29 (6%) 31 (6%) 0.8
1 to 3 222 (46%) 220 (43%)
>3 238 (49%) 260 (51%)
Histopathology Ductal 428 (88%) 427 (84%) 0.1
Nonductal 61 (12%) 84 (16%)
Malignancy grade (ductal 
only)
Grade 1 98 (23%) 97 (23%) 0.7
Grade 2 213 (50%) 223 (52%)
Grade 3 117 (27%) 107 (25%)
ER Positive 327 (67%) 344 (67%) 0.4
Negative 160 (33%) 167 (33%)
Unknown 2 (0%) 0 (0%)
PgR Positive 283 (58%) 313 (61%) 0.3
Negative 205 (42%) 198 (39%)
Unknown 1 (0%) 0 (0%)
HER2 Negative 376 (77%) 404 (79%) 0.6
Positive 110 (22%) 106 (21%)
Unknown 3 (1%) 1 (0%)
CA IX Negative 386 (79%) 408 (80%) 0.3
Positive 80 (16%) 71 (14%)
Unknown 23 (5%) 32 (6%)
Shown is the distribution of various clinicopathological parameters, including oestrogen receptor (ER), progesterone receptor (PgR), human 
epideraml growth factor receptor (HER)2 and carbonic anhydrase (CA) IX among 1,000 high-risk breast cancer patients randomly assigned to 
receive or not receive postmastectomy radiotherapy.Page 5 of 10
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or ≥ 30% invasive tumour staining did not improve the predic-
tive value of positive CA IX staining (data not presented).
Discussion
None of the three hypotheses was verified within this 945-
patient subgroup in which CA IX staining was successfully
applied. CA IX was not an independent prognostic marker of
OS, DSS, DM, or LRR when analyzed in the total group of 945
patients or when analyzed in any of the two randomization
arms. Furthermore, no significantly smaller reduction in survival
or LRR after PMRT was found in CA IX positive patients as
compared with CA IX negative patients.
The subgroup of 1,000 patients was representative of the total
cohort of 3,083 patients, with patients being well distributed
between the two randomization arms and producing similar
outcome data as observed among the total 3,083 patients
[23]. Hence, the likelihood that the findings are due to selec-
tion bias is minimal.
It appears that CA IX is only a weak, nonindependent prognos-
tic marker, because correction for apparently stronger prog-
nostic markers such as positive nodes, tumour size,
malignancy grade, hormone receptor status, HER2 status,
menopausal status/systemic treatment and randomization
eliminated the effect of CA IX status. Previously, positive CA
IX staining was found to be an independent prognostic marker
of poor survival in breast cancer in just a few studies
[7,8,13,14]. Brennan and coworkers [8] found the prognostic
value of CA IX among premenopausal women to be restricted
to those women treated with tamoxifen and, among women
who were not treated with tamoxifen, to those with one to three
positive lymph nodes. In disagreement with those findings, we
found CA IX not to be an independent prognostic marker of
OS within the subgroup of premenopausal women, either in
the whole subgroup or in those with one to three positive
lymph nodes. However, we found CA IX to be an independent
prognostic marker for OS in the subgroup of premenopausal
women with more than three positive lymph nodes. However,
the statistical significance disappeared if hormonal receptor
Table 3
Distribution of clinicopathological parameters: CA IX positive versus CA IX negative high-risk breast cancer patients
CA IX positive CA IX negative χ2/P value
All 151 (16%) 794 (84%)
Protocol Pre (DBCG82b) 89 (59%) 447 (56%) 0.5
Post (DBCG82c) 62 (41%) 347 (44%)
Tumour size (mm) <21 48 (32%) 289 (36%) 0.5
21 to 50 81 (54%) 393 (49%)
>50 22 (15%) 112 (14%)
Positive nodes None 6 (3%) 50 (6%) 0.5
1 to 3 70 (46%) 346 (44%)
>3 75 (50%) 398 (50%)
Histopathology Ductal 133 (88%) 680 (86%) 0.4
Nonductal 18 (12%) 114 (14%)
Malignancy grade Grade 1 18 (12%) 166 (21%) P < 0.0001
Grade 2 56 (37%) 357 (45%)
Grade 3 59 (39%) 157 (20%)
Nonductal 18 (12%) 114 (14%)
ER Positive 50 (33%) 581 (73%) P < 0.0001
Negative 101 (67%) 213 (27%)
PgR Positive 47 (31%) 506 (64%) P < 0.0001
Negative 104 (69%) 288 (36%)
HER2 Negative 101 (33%) 636 (80%) P < 0.0001
Positive 50 (67%) 636 (80%)
Shown is the distribution of various clinicopathological parameters among carbonic anhydrase (CA) IX positive and CA IX negative high-risk 
breast cancer patients randomized to receive or not receive postmastectomy radiotherapy. ER, oestrogen receptor; HER, human epidermal 
growth factor; PgR, progesterone receptor.Page 6 of 10
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Available online http://breast-cancer-research.com/content/10/2/R24status was excluded from the multivariate regression analysis,
as was the case in the analyses conducted by Brennan and
coworkers. Excluding hormone receptor from the analyses,
could be justified by CA IX being an intervening variable in ER
down-regulation. In accordance herewith, hypoxia and ER
downregulation have been linked in some studies [24-26]. Fur-
thermore, in accordance with the findings presented by Bren-
nan and coworkers, we found CA IX positivity to be
significantly associated with ER and PgR negative status in 2
× 2 tables; it was also significantly associated with OS in mul-
tivariate analyses within the subgroup of postmenopausal
women (all treated with tamoxifen), and within the total sub-
group of ER-positive patients and the subgroup of ER-positive
postmenopausal women treated with tamoxifen. Indeed, CA IX
was a stronger prognostic marker for OS among postmeno-
pausal women as was hormone receptor status.
Hence, CA IX may be a predictor of response to tamoxifen.
However, the predictive value of CA IX for response to
tamoxifen treatment was previously examined and no evidence
of this was found [8]. In addition, no evidence was found link-
ing hypoxia-inducible factor-1 with response to tamoxifen [27].
Performing further subgroup analyses, we found that the inde-
pendent prognostic value of CA IX for OS was restricted to
postmenopausal women randomly assigned to radiotherapy,
which suggests that CA IX status may predict response to
radiotherapy. However, in the present study we found no evi-
dence of an association between CA IX and response to radi-
otherapy, either in terms of survival or LRR. Kaplan-Meier
probability plots showed an improved OS after PMRT within
the two subgroups of CA IX negative and CA IX positive
women (15-year OS probabilities improved by 9% and 7%,
respectively). The HR was significant only in the large sub-
Table 4
Hazard ratios
CA IX positive (n = 151) CA IX negative (n = 794)
Overall mortality 0.87 (0.60–1.27) 0.82 (0.69–0.97)
Disease-specific mortality 0.83 (0.55–1.27) 0.76 (0.63–0.93)
Distant metastases 0.83 (0.54–1.25) 0.76 (0.63–0.91)
Locoregional recurrence 0.23 (0.08–0.61) 0.16 (0.09–0.28)
Presented are hazard ratios (95% confidence intervals) of overall mortality, disease-specific mortality, distant metastases and loco-regional 
recurrence probabilities after postmastectomy radiotherapy in carbonic anhydrase (CA) IX positive and in CA IX negative high-risk breast cancer 
patients.
Figure 2
Overall survival in high-risk breast cancer patients. Shown are Kaplan-Meier probability plots of overall survival in high-risk breast cancer patients as 
a function of randomization to postmastectomy radiotherapy (RT) within the subgroups of carbonic anhydrase (CA) IX negative and CA IX positive 
patients. The values given in parentheses after hazard ratios (HRs) are the 95% confidence intervals.Page 7 of 10
(page number not for citation purposes)
Breast Cancer Research    Vol 10 No 2    Kyndi et al.group of patients who were 813 CA IX negative, but this is to
be expected because an anticipated improvement in survival
of about 8% to 10% would not be expected to be statistically
significant in a subgroup of only 151 CA IX positive patients.
To summarize, that CA IX may have potential prognostic value
for survival among postmenopausal women treated with
radiotherapy and tamoxifen cannot be excluded. It should be
kept in mind, however, that we did not find CA IX to be an
independent prognostic marker within the large series of 945
patients or within either of the two randomization arms. Cau-
tion should therefore be exercised when interpreting results
obtained from extended subgroup analyses.
The fact that CA IX did not predict outcome after PMRT within
this series of 945 patients is in disagreement with other work
[7], which suggested a reduction in survival after PMRT that
was restricted to CA IX positive patients. However, that study
included TMAs from only 160 patients and defined tumour
positivity as staining of at least one invasive tumour cell in a
section, which we have demonstrated may have an inferior
reproducibility as compared with using a cut-point of ≥ 10%.
Brennan and coworkers [8] suggested that positive CA IX
might be a marker of resistance to radiotherapy among
patients with one to three positive lymph nodes. We found no
evidence of this, with similar reductions in OS after PMRT for
CA IX negative and CA IX positive patients with one to three
positive lymph nodes. Our results indicate that CA IX alone is
not a specific marker of resistance to radiotherapy and may be
the presence of hypoxic tumour cells, which is in accordance
with other reports from our laboratory. In vitro studies have
shown that increasing levels of hypoxia induced a rise in CA IX
expression, which was clearly pH dependent. CA IX increased
in response to decreasing oxygen tension at pH above 6.5 but,
despite decreasing oxygen tension, did not increase in the
most acidic range measured in tumours (pH 6.3 to 6.5); this
suggests that the relation between CA IX and hypoxia is more
complicated. Another study examining 57 head and neck
squamous cell carcinomas found no correlation between
immunohistochemically determined CA IX status and tumour
oxygenation status using partial oxygen tension needle elec-
trodes [28]. Finally, a recent study [9] revealed that CA IX,
identified using immunohistochemistry, did not predict
response to nimorazole (a hypoxic sensitizer) in a series of 320
patients with head and neck squamous cell carcinomas.
However, it should be borne in mind that using TMAs for immu-
nohistochemical examination of CA IX underestimates the fre-
quency of CA IX positive tumours. Invasive tumor cells do not
express CA IX diffusely but rather focally and more frequently
in tumor cells near necrotic areas [12,13,22,29]. Frequencies
of CA IX positive tumours of varying magnitude have been
reported in studies examining whole sections (46% to 48%)
[10,13] and TMAs (18% to 28%) [7,11], and the same ten-
dency was found in our pilot study examining agreement
between CA IX stainings, albeit not as marked. In addition, we
found that adding one extra TMA biopsy slightly increased the
frequency of CA IX positive tumors but adding two or three
extra TMA biopsies did not further increase the CA IX fre-
quency. However, this contrasts with findings reported by
Goethals and coworkers [30], who applied staining for CA IX
to colon cancer. They concluded that in order to reduce the
number of CA IX negative cases, four or five punches from
each tumour was apparently optimal. We opted to use central
cores in the DBCG82 study rather than peripheral cores,
based on the findings of the pilot study. This could be a point
of criticism because in our study we did not find strictly the
same amount of invasive tumour cells in central and peripheral
biopsies; also, the percentages of assessable tumour cells in
each core differed between different tumour blocks, because
of differences in size of the invasive areas. However, in general
the original tumours were large, because they were selected
only if at least three paraffin-embedded tumour blocks
containing verified invasive tumour could be located. For these
reasons, this shortcoming of our study probably has little
impact on our findings. An alternative is to use whole sections
instead of TMAs. However, the reproducibility of findings in
whole sections from two different paraffin blocks from the
same tumour was not notably better than comparing a central
TMA biopsy with the corresponding whole section in our
study. It has been argued that a whole section is still only a
small fraction of the entire tumour, and when one looks at
something rare and unequally distributed, one might derive the
most accurate picture of that distribution by looking at a small
proportion of tissue such as a TMA biopsy. In addition, it must
be stressed that the set up in our pilot study (as well as in the
study by Goethals and colleagues [30]) was not designed to
evaluate the accuracy of TMAs, because these were not com-
pared with the 'truth' but were compared with whole sections,
which account for only part of the truth.
Conclusion
This is the largest study of CA IX to date; in 945 high-risk
breast cancer patients randomly assigned to receive PMRT
plus systemic therapy or systemic therapy alone, we found CA
IX to be significantly associated with OS and DSS but not with
DM or LRR in univariate analyses. CA IX was not an independ-
ent prognostic marker for any of the end-points analyzed. How-
ever, we cannot rule out that CA IX may be an independent
prognostic marker for survival among different subgroups of
women. Among other findings, we identified a potential asso-
ciation between CA IX and response to tamoxifen in postmen-
opausal women treated with tamoxifen and PMRT and in the
subgroup of hormone receptor positive women. CA IX was not
associated with response to PMRT. Fifteen-year OS probabil-
ities were improved by 9% and 7% after PMRT for the sub-
groups of CA IX negative and CA IX positive patients,
respectively. The improvement in OS after PMRT did not reach
statistical significance in the small subgroup of 151 CA IX
positive patients.Page 8 of 10
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